COSMETIC COMPOSITION WITH A C-GLYCOSIDE, NIACINAMIDE AND PANTHENOL

Abstract

COSMETIC COMPOSITION WITH A C-GLYCOSIDE, NIACINAMIDE, AND PANTHENOL The invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, by weight relative to the total weight of the composition: 1% to 25% by weight of the active substance of at least one C-glycoside of formula (I), 1% to 10% by weight of the active substance of a compound selected from niacinamide and its derivatives, and 0.5% to 10% by weight of the active substance of panthenol. The invention also relates to a non-therapeutic cosmetic treatment method for keratinous materials, particularly skin, comprising applying a composition according to the invention to the keratinous materials, particularly skin, and using the composition of the invention cosmetically to reduce the signs of skin aging. Figure for abstract: none

Description

Title of the invention: Cosmetic composition with a C-glycoside, niacinamide and panthenol

[0001] The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one C-glycoside of formula (I), niacinamide or one of its derivatives and panthenol, in given amounts.

[0002] The skin is a tissue in which the cells are contiguous and firmly linked to one another. The cutaneous tissue forms an external layer comprising sebaceous or sweat glands and hair follicles. The skin, and in particular the scalp, are constantly renewed epithelia. Renewal, or desquamation, is a coordinated and finely regulated process which leads to the elimination of the surface cells, in an imperceptible and invisible manner.

[0003] Human skin is composed of two compartments, namely a surface compartment (the epidermis) and a deep compartment (the dermis).

[0004] The epidermis is traditionally divided into a basal layer of keratinocytes constituting the germinative layer of the epidermis, a so-called spinous layer, composed of several layers of polyhedral cells located on the germinative layers, one to three layers called granular layers (stratum granulosum), composed of flat cells containing distinct cytoplasmic inclusions, grains of kera-tohyalin and finally, a set of upper layers called horny layers (stratum corneum), composed of keratinocytes called comeocytes in the terminal stage of their differentiation.

[0005] One of the current trends among consumers is to want to look young for as long as possible. They therefore seek to reduce the signs of skin aging, for example wrinkles and fine lines, thinning of the epidermis, strengthening the skin barrier function and / or the appearance of sagging and wrinkled skin, and / or seek to delay the phenomenon of skin aging. Many products intended to maintain the skin's radiance and the absence of wrinkles, the signs of young skin, for as long as possible have therefore been developed. These products comprise one or more biological active agents which have demonstrated biological efficacy with respect to skin aging.

[0006] However, the performance of these products remains to be improved.

[0007] Therefore, there is a need for products offering one or more anti-aging benefits. In particular, there is a need for products offering a more even complexion, and / or reduced / tightened pores, and / or a fatigue-relieving effect, and / or reduced wrinkles and / or fine lines and / or a plumper appearance of the skin and / or more supple skin.

[0008] The inventors have now discovered that the combination of a C-glycoside of formula (I) with niacinamide and panthenol, in given amounts, satisfactorily provides one or more anti-aging benefits and solves the above problem.

[0009] The invention thus relates to a cosmetic composition comprising, in a physiologically acceptable medium, by weight relative to the total weight of the composition: • from 1% to 25% by weight of active substance of at least one C-glycoside of formula (I), • from 1% to 10% by weight of active substance of a compound chosen from niacinamide and its derivatives and • from 0.5% to 10% by weight of active substance panthenol.

[0010] The invention also relates to a non-therapeutic cosmetic care method for keratinous materials, in particular for the skin, comprising the application to the keratinous materials, in particular the skin, of a composition according to the invention.

[0011] The invention also relates to the cosmetic use of the composition of the invention for reducing the signs of skin aging.

[0012] The association of a C-glycoside of formula (I) with niacinamide and panthenol, in given quantities, is also called “the complex of the invention”.

[0013] As shown in the examples, said combination proves to have a superior or better effect, in particular a potentiating effect of the C-glycoside. Indeed, niacinamide or one of its derivatives, and panthenol, increase the action of the C-glycoside, in particular by potentiating the action of the C-glycoside.

[0014] According to the invention, the expression “potentiating effect” aims to describe a response or an effect resulting from the implementation of a combination of elements greater than the sum of the responses or effects resulting from the separate implementation of these elements.

[0015] According to the invention, “physiologically acceptable medium” designates a medium compatible with keratinous materials such as skin, mucous membranes, nails and / or hair. C-glycoside

[0016] The C-glycoside according to the invention has the following general formula (I):

[0017] [Chem.l] ,XB (I)

[0018] in which: • R represents: • a linear alkyl radical saturated in C1 to C20, in particular in C1 to C10, or unsaturated in C2 to C20, in particular in C3 to C10, or a branched or cyclic alkyl radical saturated or unsaturated in C3 to C20, in particular in C4 to C10; • a linear hydrofluoro- or perfluoro-alkyl radical saturated in C1 to C20, in particular in C2 to C10, or unsaturated in C2 to C20, in particular in C2 to C10, or branched or cyclic, saturated or unsaturated, in C3 to C20, in particular in C4 to C10; • a phenyl or benzyl radical, the hydrocarbon chain forming said radicals being optionally interrupted, where appropriate, by 1, 2, 3 or more heteroatoms chosen from: • oxygen, • a sulfur, • nitrogen and • a silicone,

[0019] and being optionally substituted by at least one radical chosen from: • -OR4, • -SR4, • -NR4R5, • -COOR4, • -CONHR4, • -CN, • a halogen atom, • a C1 to C6 hydrofluoro- or perfluoro-alkyl radical and / or • a C3 to C8 cycloalkyl radical and / or • at least one optionally substituted C5 to C18 cycloalkyl, aryl, heterocyclic radical, • where R4 and R5 may represent, independently of one another, a hydrogen atom, or a saturated C1 to C30, in particular C3 to C12, or unsaturated C2 to C30, in particular C3 to C12, linear, or saturated or unsaturated C3 to C30, in particular C4 to C12, branched or cyclic alkyl, perfluoroalkyl or hydrofluoroalkyl radical; or a C6 to C10 aryl radical, • X represents a radical chosen from -CO-, -CH(OH)- or -CH(NH2)- and, preferably, a -CH(OH)- group; • S represents a monosaccharide or a polysaccharide including up to 20 sugar units, in particular up to 6 sugar units, in the form of pyranose and / or furanose and of the L and / or D series, said mono- or polysaccharide being optionally substituted by a necessarily free hydroxyl group and optionally one or more optionally protected amine functions, and • the S-CH2-X bond represents a C-anomeric bond, which can be α or [3, and its physiologically acceptable salts, its solvates such as its hydrates and its isomers.

[0020] Within the scope of the present invention, "halogen" means chlorine, fluorine, bromine or iodine.

[0021] The term "aryl" refers to an aromatic ring system, such as phenyl, optionally substituted with one or more C1-C4 alkyl radicals.

[0022] The term "C3-C8 cycloalkyl" means an aliphatic ring system having from 3 to 8 carbon atoms, including, for example, cyclopropyl, cyclopentyl and cyclohexyl.

[0023] Among the alkyl groups suitable for implementing the invention, mention may be made in particular of the methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, n-hexyl, cyclopropyl cyclopentyl, cyclohexyl and allyl groups.

[0024] A C-glycoside may satisfy formula (I) for which S may represent a monosaccharide or a polysaccharide comprising up to 6 sugar units, in the form of pyranose and / or furanose and of the L and / or D ranges, said mono- or polysaccharide having at least one necessarily free hydroxyl function and / or optionally one or more necessarily protected amine functions, X and R otherwise retaining all the definitions above.

[0025] Advantageously, a monosaccharide according to the invention may be chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose or L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and advantageously denotes D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose and in particular D-xylose.

[0026] More specifically, a polysaccharide according to the invention containing up to 6 sugar units may be chosen from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid chosen from D-iduronic acid or D-glucuronic acid with a hexosamine chosen from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least one xylose which may advantageously be chosen from xylobiose, methyl-[3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and particularly, xylobiose which is composed of two xylose molecules linked by a 1-4 bond.

[0027] More specifically, S can represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose and in particular, D-xylose.

[0028] According to one embodiment of the invention, a C-glycoside satisfying formula (I) may be used, for which R represents a linear saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C3 to C10, alkyl radical, or a branched or cyclic saturated or unsaturated C3 to C20, in particular particular in C4 to C10, and optionally substituted as described above, S and X also retaining all the definitions given above.

[0029] In particular, R may denote a linear C1-C4, in particular C1-C2, radical, optionally substituted by -OH, -COOH or -COOR"2, R"2 being a saturated linear C1-C4, in particular methyl, alkyl radical. In particular, R may denote an unsubstituted linear C1-C4, in particular C1-C2, alkyl radical, in particular methyl.

[0030] Among the C-glycosides of formula (I), it is particularly possible to use those for which: • R represents a linear saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C3 to C10, alkyl radical, or a branched or cyclic saturated or unsaturated C3 to C20, in particular C4 to C10, alkyl radical and optionally substituted as described above; • S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose and, in particular, D-xylose; • X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)- and, preferably, a -CH(OH)- group.

[0031] More specifically, a C-glycoside of formula (I) is used, for which: • R denotes a linear C1-C4 radical, in particular C1-C3, optionally substituted by -OH, -COOH or -COOR"2, R"2 being a saturated linear C1-C4 alkyl radical, in particular methyl; • S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose and, in particular, D-xylose; • X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH2)- and, preferably, a -CH(OH)- group.

[0032] According to one embodiment, a C-glycoside of formula (I) can be used, for which: • R denotes an unsubstituted linear C1-C4, in particular C1-C2, alkyl radical, in particular methyl; • S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose and, in particular, D-xylose; • X represents a group chosen from -CO-, -CH(OH)-, -CH(NH2)- and preferably, a -CH(OH)- group.

[0033] Acceptable salts for non-therapeutic use of the compounds described in the present invention include conventional non-toxic salts of said compounds, such as than those formed from organic or inorganic acids. For example, mention may be made of salts of mineral acids, such as sulfuric acid, hydrochloric acid, hydrobromic acids, hydroiodic acid, phosphoric acid, boric acid. Mention may also be made of salts of organic acids, which may include one or more carboxylic, sulfonic or phosphonic acid groups. They may consist of linear, branched or cyclic aliphatic acids or, of course, aromatic acids. These acids may further include one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups. Mention may be made in particular of propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid.

[0034] When the compound of formula (I) includes an acid group, the acid group(s) may be neutralized by a mineral base, such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2 or Zn(OH)2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may include one or more nitrogen and / or oxygen atoms and may therefore include, for example, one or more alcohol functions; in particular, amino-2-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol or 2-amino-2-(hydroxymethyl)-1,3-propanediol may be mentioned. Other examples include lysine or 3-(dimethylamino)propylamine.

[0035] Acceptable solvates for the compounds described in the present invention include conventional solvates such as those formed during the final preparation step of said compounds due to the presence of solvents. Examples include solvates due to the presence of water or linear or branched alcohols, such as ethanol or isopropanol.

[0036] Among the C-glycosides of formula (I), used according to the invention, the following compounds are the subject of very particular attention:

[0037] 1. C-[3-D-xylopyranoside-n-propane-2-one;

[0038] 2. CaD-xylopyranoside-n-propane-2-one;

[0039] 3. l-[2-(3-hydroxy-propylamino)-propyl]-C-[3-D-xylopyranose;

[0040] 4. l-[2-(3-hydroxy-propylamino)-propyl]-CaD-xylopyranose;

[0041] 5. C-[3-D-xylopyranoside-2-hydroxy-propane;

[0042] 6. CaD-xylopyranoside-2-hydroxy-propane; 7. C-[3-D-xylopyranoside-2-amino-propane; 8. CaD-xylopyranoside-2-amino-propane;

[0045] 9. C-[3-D-xylopyranoside-2-phenylamino-propane;

[0046] 10. CaD-xylopyranoside-2-phenylamino-propane;

[0047] 11. 3-Methyl-4-(C-[3-D-xylopyranoside)-butyric acid ethyl ester;

[0048] 12. 3-Methyl-4-(CaD-xylopyranoside)-butyric acid ethyl ester;

[0049] 13. 6-(C-[3-D-xylopyranoside)-5-keto-hexanoic acid;

[0050] 14. 6-(CaD-xylopyranoside)-5-keto-hexanoic acid;

[0051] 15. 6-(C-[3-D-xylopyranoside)-5-hydroxy-hexanoic acid;

[0052] 16. 6-(CaD-xylopyranoside)-5-hydroxy-hexanoic acid;

[0053] 17. 6-(C-[3-D-xylopyranoside)-5-amino-hexanoic acid;

[0054] 18. 6-(CaD-xylopyranoside)-5-amino-hexanoic acid;

[0055] 19. 6-(C-[3-D-xylopyranoside)-5-phenylamino-hexanoic acid;

[0056] 20. 6-(CaD-xylopyranoside)-5-phenylamino-hexanoic acid;

[0057] 21. l-(C-[3-D-xylopyranoside)-hexane-2,6-diol;

[0058] 22. l-(CaD-xylopyranoside)-hexane-2,6-diol;

[0059] 23. 5-(C-[3-D-xylopyranoside)-4-keto-pentanoic acid;

[0060] 24. 5-(CaD-xylopyranoside)-4-keto-pentanoic acid;

[0061] 25. 5-(C-[3-D-xylopyranoside)-4-hydroxy-pentanoic acid;

[0062] 26. 5-(CaD-xylopyranoside)-4-hydroxy-pentanoic acid;

[0063] 27. 5-(C-[3-D-xylopyranoside)-4-amino-pentanoic acid;

[0064] 28. 5-(CaD-xylopyranoside)-4-amino-pentanoic acid;

[0065] 29. 5-(C-[3-D-xylopyranoside)-4-phenylamino-pentanoic acid;

[0066] 30. 5-(CaD-xylopyranoside)-4-phenylamino-pentanoic acid;

[0067] 31. l-(C-[3-D-xylopyranoside)-pentane-2,5-diol ;

[0068] 32. l-(C-a-D-xylopyranoside)-pentane-2,5-diol ;

[0069] 33. l-(C-[3-D-fucopyranoside)-propane-2-one ;

[0070] 34. l-(C-a-D-fucopyranoside)-propane-2-one ;

[0071] 35. l-(C-[3-L-fucopyranoside)-propane-2-one ;

[0072] 36. l-(C-a-L-fucopyranoside)-propane-2-one ;

[0073] 37. l-(C-[3-D-fucopyranoside)-2-hydroxy-propane ;

[0074] 38. l-(C-a-D-fucopyranoside)-2-hydroxy-propane ;

[0075] 39. l-(C-[3-L-fucopyranoside)-2-hydroxy-propane ;

[0076] 40. l-(C-a-L-fucopyranoside)-2-hydroxy-propane ;

[0077] 41. l-(C-[3-D-fucopyranoside)-2-amino-propane ;

[0078] 42. l-(C-a-D-fucopyranoside)-2-amino-propane ;

[0079] 43. l-(C-[3-L-fucopyranoside)-2-amino-propane ;

[0080] 44. l-(C-a-L-fucopyranoside)-2-amino-propane ;

[0081] 45. l-(C-[3-D-fucopyranoside)-2-phenylamino-propane;

[0082] 46. l-(CaD-fucopyranoside)-2-phenylamino-propane;

[0083] 47. l-(C-[3-L-fucopyranoside)-2-phenylamino-propane;

[0084] 48. l-(CaL-fucopyranoside)-2-phenylamino-propane;

[0085] 49. 3-Methyl-4-(C-[3-D-fucopyranoside)-butyric acid ethyl ester;

[0086] 50. 3-Methyl-4-(CaD-fucopyranoside)-butyric acid ethyl ester;

[0087] 51. 3-Methyl-4-(C-[3-L-fucopyranoside)-butyric acid ethyl ester;

[0088] 52. 3-Methyl-4-(CaL-fucopyranoside)-butyric acid ethyl ester;

[0089] 53. 6-(C-[3-D-fucopyranoside)-5-keto-hexanoic acid;

[0090] 54. 6-(CaD-fucopyranoside)-5-keto-hexanoic acid;

[0091] 55. 6-(C-[3-L-fucopyranoside)-5-keto-hexanoic acid;

[0092] 56. 6-(CaL-fucopyranoside)-5-keto-hexanoic acid;

[0093] 57. 6-(C-[3-D-fucopyranoside)-5-hydroxy-hexanoic acid;

[0094] 58. 6-(CaD-fucopyranoside)-5-hydroxy-hexanoic acid;

[0095] 59. 6-(C-[3-L-fucopyranoside)-5-hydroxy-hexanoic acid;

[0096] 60. 6-(CaL-fucopyranoside)-5-hydroxy-hexanoic acid;

[0097] 61. 6-(C-[3-D-fucopyranoside)-5-amino-hexanoic acid;

[0098] 62. 6-(CaD-fucopyranoside)-5-amino-hexanoic acid;

[0099] 63. 6-(C-[3-L-fucopyranoside)-5-amino-hexanoic acid;

[0100] 64. 6-(CaL-fucopyranoside)-5-amino-hexanoic acid;

[0101] 65. l-(C-[3-D-fucopyranoside)-hexane-2,6-diol;

[0102] 66. l-(CaD-fucopyranoside)-hexane-2,6-diol;

[0103] 67. l-(C-[3-L-fucopyranoside)-hexane-2,6-diol;

[0104] 68. l-(CaL-fucopyranoside)-hexane-2,6-diol;

[0105] 69. 5-(C-[3-D-fucopyranoside)-4-keto-pentanoic acid;

[0106] 70. 5-(CaD-fucopyranoside)-4-keto-pentanoic acid;

[0107] 71. 5-(C-[3-L-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid;

[0108] 72. 5-(CaL-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid;

[0109] 73. 5-(C-[3-D-fucopyranoside)-4-hydroxy-pentanoic acid;

[0110] 74. 5-(CaD-fucopyranoside)-4-hydroxy-pentanoic acid; [YES] 75. 5-(C-[3-L-fucopyranoside)-4-hydroxy-pentanoic acid;

[0112] 76. 5-(CaL-fucopyranoside)-4-hydroxy-pentanoic acid;

[0113] 77. 5-(C-[3-D-fucopyranoside)-4-amino-pentanoic acid;

[0114] 78. 5-(CaD-fucopyranoside)-4-amino-pentanoic acid;

[0115] 79. 5-(C-[3-L-fucopyranoside)-4-amino-pentanoic acid;

[0116] 80. 5-(CaL-fucopyranoside)-4-amino-pentanoic acid;

[0117] 81. l-(C-[3-D-fucopyranoside)-pentane-2,5-diol;

[0118] 82. l-(CaD-fucopyranoside)-pentane-2,5-diol;

[0119] 83. l-(C-[3-L-fucopyranoside)-pentane-2,5-diol;

[0120] 84. l-(CaL-fucopyranoside)-pentane-2,5-diol;

[0121] 85. 1-(C-[3-D-glucopyranosyl)-2-hydroxy-propane;

[0122] 86. l-(CaD-glucopyranosyl)-2-hydroxy-propane;

[0123] 87. l-(C-[3-D-glucopyranosyl)-2-amino-propane;

[0124] 88. l-(CaD-glucopyranosyl)-2-amino-propane;

[0125] 89. 1-(C-[3-D-glucopyranosyl)-2-phenylamino-propane;

[0126] 90. l-(CaD-glucopyranosyl)-2-phenylamino-propane;

[0127] 91. 3-Methyl-4-(C-[3-D-glucopyranosyl)-butyric acid ethyl ester;

[0128] 92. 3-Methyl-4-(CaD-glucopyranosyl)-butyric acid ethyl ester;

[0129] 93. 6-(C-[3-D-glucopyranosyl)-5-keto-hexanoic acid;

[0130] 94. 6-(CaD-glucopyranosyl)-5-keto-hexanoic acid;

[0131] 95. Acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-hexanoïque ;

[0132] 96. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-hexanoïque ;

[0133] 97. Acide 6-(C-[3-D-glucopyranosyl)-5-amino-hexanoïque ;

[0134] 98. Acide 6-(C-a-D-glucopyranosyl)-5-amino-hexanoïque ;

[0135] 99. Acide 6-(C-[3-D-glucopyranosyl)-5-phénylamino-hexanoïque ;

[0136] 100. Acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-hexanoïque ;

[0137] 101. l-(C-[3-D-glucopyranosyl)-hexane-2,6-diol ;

[0138] 102. l-(C-a-D-glucopyranosyl)-hexane-2,6-diol ;

[0139] 103. Acide 6-(C-[3-D-glucopyranosyl)-5-céto-pentanoïque ;

[0140] 104. Acide 6-(C-a-D-glucopyranosyl)-5-céto-pentanoïque ;

[0141] 105. Acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-pentanoïque ;

[0142] 106. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoïque ;

[0143] 107. Acide 6-(C-[3-D-glucopyranosyl)-5-amino-pentanoïque ;

[0144] 108. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoïque ;

[0145] 109. Acide 6-(C-[3-D-glucopyranosyl)-5-phénylamino-pentanoïque ;

[0146] 110. Acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-pentanoïque ;

[0147] 111. l-(C-[3-D-glucopyranosyl)-pentane-2,5-diol ;

[0148] 112. l-(C-a-D-glucopyranosyl)-pentane-2,5-diol ;

[0149] 113. l-(C-[3-D-galactopyranosyl)-2-hydroxy-propane ;

[0150] 114. l-(C-a-D-galactopyranosyl)-2-hydroxy-propane ;

[0151] 115. l-(C-[3-D-galactopyranosyl)-2-amino-propane ;

[0152] 116. l-(C-a-D-galactopyranosyl)-2-amino-propane ;

[0153] 117. l-(C-[3-D-galactopyranosyl)-2-phénylamino-propane ;

[0154] 118. l-(C-a-D-galactopyranosyl)-2-phénylamino-propane ;

[0155] 119. 3-Methyl-4-([3-D-galactopyranosyl)-butyric acid ethyl ester;

[0156] 120. 3-Methyl-4-(aD-galactopyranosyl)-butyric acid ethyl ester;

[0157] 121. 6-(C-[3-D-galactopyranosyl)-5-keto-hexanoic acid;

[0158] 122. 6-(CaD-galactopyranosyl)-5-keto-hexanoic acid;

[0159] 123. 6-(C-[3-D-galactopyranosyl)-5-hydroxy-hexanoic acid;

[0160] 124. 6-(CaD-galactopyranosyl)-5-hydroxy-hexanoic acid;

[0161] 125. 6-(C-[3-D-galactopyranosyl)-5-amino-hexanoic acid;

[0162] 126. 6-(CaD-galactopyranosyl)-5-amino-hexanoic acid;

[0163] 127. 6-(C-[3-D-galactopyranosyl)5-phenylamino-hexanoic acid;

[0164] 128. 6-(CaD-galactopyranosyl)5-phenylamino-hexanoic acid;

[0165] 129. l-(C-[3-D-galactopyranosyl)-hexane-2,6-diol;

[0166] 130. l-(CaD-galactopyranosyl)-hexane-2,6-diol;

[0167] 131. 6-(C-[3-D-galactopyranosyl)-5-keto-pentanoic acid;

[0168] 132. 6-(CaD-galactopyranosyl)-5-keto-pentanoic acid;

[0169] 133. 6-(C-[3-D-galactopyranosyl)-5-hydroxy-pentanoic acid;

[0170] 134. 6-(CaD-galactopyranosyl)-5-hydroxy-pentanoic acid;

[0171] 135. 6-(C-[3-D-galactopyranosyl)-5-amino-pentanoic acid;

[0172] 136. 6-(CaD-galactopyranosyl)-5-amino-pentanoic acid;

[0173] 137. 6-(C-[3-D-galactopyranosyl)-5-phenylamino-pentanoic acid;

[0174] 138. 6-(CaD-galactopyranosyl)-5-phenylamino-pentanoic acid;

[0175] 139. l-(C-[3-D-galactopyranosyl)-pentane-2,6-diol;

[0176] 140. l-(CaD-galactopyranosyl)-pentan-2,6-diol;

[0177] 141. l-(C-[3-D-fucofuranosyl)-propane-2-one;

[0178] 142. l-(CaD-fucofuranosyl)-propane-2-one;

[0179] 143. l-(C-[3-L-fucofuranosyl)-propane-2-one;

[0180] 144. l-(CaL-fucofuranosyl)-propane-2-one;

[0181] 145. 3'-(acetamido-C-[3-D-glucopyranosyl)-propane-2'-on;

[0182] 146. 3'-(acetamido-CaD-glucopyranosyl)-propan-2'-one;

[0183] 147. l-(acetamido-C-[3-D-glucopyranosyl)-2-hydroxyl-propane;

[0184] 148. l-(acetamido-C-[3-D-glucopyranosyl)-2-amino-propane;

[0185] 149. l-(acetamido-C-[3-D-glucopyranosyl)-2-phenylamino-propane;

[0186] 150. l-(acetamido-CaD-glucopyranosyl)-2-phenylamino-propane;

[0187] 151. 3-Methyl-4-(acetamido-C-[3-D-]-ethyl ester

[0188] glucopyranosyl)-butyric acid

[0189] 152. 3-Methyl-4-(acetamido-CaD-)-ethyl ester

[0190] glucopyranosyl)-butyric acid

[0191] 153. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-keto-hexanoic acid;

[0192] 154. 6-(acetamido-CaD-glucopyranosyl)-5-keto-hexanoic acid;

[0193] 155. 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-hexanoic acid;

[0194] 156. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-hexanoic acid;

[0195] 157. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-amino-hexanoic acid;

[0196] 158. 6-(acetamido-CaD-glucopyranosyl)-5-amino-hexanoic acid;

[0197] 159. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-hexanoic acid;

[0198] 160. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-hexanoic acid;

[0199] 161. l-(acetamido-C-[3-D-glucopyranosyl)-hexane-2,6-diol;

[0200] 162. l-(acetamido-CaD-glucopyranosyl)-hexane-2,6-diol;

[0201] 163. 6-(acetamido-C-[3-D-glucopyranosyl)-5-keto-pentanoic acid;

[0202] 164. 6-(acetamido-CaD-glucopyranosyl)-5-keto-pentanoic acid;

[0203] 165. 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-pentanoic acid;

[0204] 166. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-pentanoic acid;

[0205] 167. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-amino-pentanoic acid;

[0206] 168. 6-(acetamido-CaD-glucopyranosyl)-5-amino-pentanoic acid;

[0207] 169. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-pentanoic acid;

[0208] 170. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-pentanoic acid;

[0209] 171. l-(acetamido-C-[3-D-glucopyranosyl)-pentane-2,5-diol;

[0210] 172. l-(acetamido-CaD-glucopyranosyl)-pentane-2,5-diol.

[0211] By way of illustration and not of limitation of the C-glycosides more specifically adapted to the invention, the following compounds may be mentioned in particular:

[0212] - C-[3-D-xylopyranoside-n-propane-2-one,

[0213] - C-a- D-xylopyranoside-n-propane-2-one,

[0214] - C-[3-D-xylopyranoside-2-hydroxy-propane,

[0215] - C-a- D-xylopyranoside-2-hydroxy-propane,

[0216] - l-(C-[3-D-fucopyranoside)-propane-2-one,

[0217] - l-(C-a-D-fucopyranoside)-propane-2-one,

[0218] - l-(C-[3-L-fucopyranoside)-propane-2-one,

[0219] - l-(C-a-L-fucopyranoside)-propane-2-one,

[0220] - l-(C-[3-D-fucopyranoside)-2-hydroxy-propane,

[0221] - l-(C-a-D-fucopyranoside)-2-hydroxy-propane,

[0222] - l-(C-[3-L-fucopyranoside)-2-hydroxy-propane,

[0223] - l-(C-a-L-fucopyranoside)-2-hydroxy-propane,

[0224] - l-(C-[3-D-Glucopyranosyl)-2-hydroxyl-propane,

[0225] - l-(C-a-D-Glucopyranosyl)-2-hydroxyl-propane,

[0226] - l-(C-[3-D-galactopyranosyl)-2-hydroxyl-propane,

[0227] - l-(CaD-galactopyranosyl)-2-hydroxyl-propane

[0228] - l-(C-[3-D-fucofuranosyl)-propane-2-one,

[0229] - l-(CaD-fucofuranosyl)-propane-2-one

[0230] - l-(C-[3-L-fucofuranosyl)-propane-2-one,

[0231] - l-(CaL-fucofuranosyl)-propane-2-one,

[0232] - C-[3-D-maltopyranoside-n-propane-2-one,

[0233] - CaD-maltopyranoside-n-propane-2-one

[0234] - C-[3-D-maltopyranoside-2-hydroxy-propane,

[0235] - CaD-maltopyranoside-2-hydroxy-propane, their isomers or their mixtures.

[0236] Preferably, C-beta-D-xylopyranoside-2-hydroxy-propane or C- alpha-D-xylopyranoside-2-hydroxy-propane is used and, more preferably, C-beta-D-xylopyranoside-2-hydroxy-propane. Preferably, a C-glycoside of formula (I) suitable for the invention may advantageously be C-beta-D-xylopyranoside-2-hydroxy-propane, whose INCI name is HY-DROXYPROPYL TETRAHYDROPYRANTRIOL, sold in particular under the name MEXORYL SBB® or MEXORYL SCN® by NOVEAL. Such a C-glycoside of formula (I) may also be present in concentrated form, i.e. in a 70% concentrated hydrophilic dispersion with active substance; such a C-glycoside is marketed under the name MEXORYL SCS® by NOVEAL.

[0237] The composition according to the invention comprises at least one C-glycoside of formula (I) with a content of 1% to 25% by weight of active substance relative to the total weight of the composition and, preferably, of 5% to 18% by weight of active substance, and more specifically of 7% to 15% by weight of active substance. Nicotinamide and / or its derivatives

[0238] Niacinamide, also called nicotinamide, vitamin PP or B3, has a structure according to the following formula (II):

[0239] [Chem.2]

[0240] The term "niacinamide derivative" preferably denotes a compound in which the amide group of niacinamide is secondary or tertiary, preferably substituted by one or two alkyl groups independently selected from C1-C4 alkyl groups and / or in which at least one hydrogen atom of the pyridine group is replaced by a C1-C4 alkyl group.

[0241] Preferably, the compound chosen from niacinamide and its derivatives is niacinamide.

[0242] We can cite, for example; the product Niacinamide PC® marketed by DSM NUTRITIONAL PRODUCTS.

[0243] The composition comprises from 1% to 10% by weight of the compound chosen from niacinamide and its derivatives relative to the total weight of the composition, preferably from 0.5% to 8% by weight, preferably from 0.7% to 5% by weight, preferably from 2% to 4% by weight.

[0244] Preferably, the composition comprises from 1% to 8% by weight of the compound chosen from niacinamide and its derivatives relative to the total weight of the composition, preferably from 1% to 5% by weight, preferably from 2% to 4% by weight. Panthenol

[0245] Panthenol (also called pantothenol) is a provitamin B5. It is structured according to the following formula (III):

[0246] [Chem.3] OH (III).

[0247] Since panthenol comprises an asymmetric carbon atom, it can be present in two enantiomers, D and L. Preferably, the panthenol is D-panthenol (or dexpanthenol).

[0248] Examples include the product D PANTHEOL CARE® marketed by BASF, D PANTHENOL marketed by DSM Nutritional Products or Hangzhou Xinfu Science & Technology.

[0249] The composition comprises from 0.5% to 10% by weight of active substance relative to the total weight of the panthenol composition, preferably from 0.7% to 8% by weight, preferably from 0.8% to 5% by weight, preferably from 0.8% to 1.5% by weight. Physiologically acceptable medium

[0250] The composition according to the invention also comprises a physiologically acceptable medium. This physiologically acceptable medium can be chosen by a person skilled in the art on the basis of general knowledge depending on the type of composition sought.

[0251] As a general rule, this medium can be anhydrous or aqueous. It can thus comprise an aqueous phase and / or a fatty phase.

[0252] Thus, preferably, said physiologically acceptable medium comprises an aqueous phase and / or a fatty phase.

[0253] A composition contemplated in the invention can be formulated in the form of a solid, semi-solid or liquid emulsion.

[0254] Preferably, the composition according to the invention is an aqueous composition.

[0255] "Aqueous composition" means any composition comprising at least 5% by weight of water relative to the total weight of the composition and, preferably, from 5 to 95% by weight and, more preferably, from 20 to 90% by weight.

[0256] Alternatively, preferably, the composition according to the present invention is anhydrous. "Anhydrous composition" means any composition comprising less than 5% by weight of water relative to the total weight of the composition and, more preferably, less than 1% of water, preferably less than 0.5% by weight of water, preferably any composition free of water.

[0257] A composition according to the invention can be administered topically.

[0258] For application to the skin, the composition may take the form, in particular, of an aqueous or oily solution; of a dispersion of the lotion or serum type; of an emulsion of liquid or semi-liquid consistency of the milk type obtained by dispersing a fatty phase in an aqueous phase (O / W), inversely (W / O), or triple O / W / O or W / O / W; of a suspension or emulsion of soft consistency of the aqueous or anhydrous cream or gel type; of microcapsules or microparticles; of vesicular dispersions of the ionic and / or non-ionic type.

[0259] When the composition comprises an aqueous phase, it comprises water, floral water and / or mineral water.

[0260] Said aqueous phase may further comprise one or more organic solvents such as a C1-C8 alcohol, in particular ethanol, isopropanol, tert-butanol, n-butanol, pentanol, hexanol, polyols such as glycerin, propylene glycol, butylene glycol, capryl / caprylic glycol, isoprene glycol, polyethylene glycol and polyol ethers.

[0261] When the composition according to the invention is in the form of an emulsion, it may optionally further comprise a surfactant, preferably in an amount of 0.01 to 30% by weight relative to the total weight of the composition. The composition according to the invention may also comprise at least one co-emulsifier which may be chosen from oxyethylenated sorbitan monostearate, fatty alcohols such as stearyl alcohol or cetyl alcohol, or esters of fatty acids and polyols such as glyceryl stearate.

[0262] The composition according to the invention may also comprise a fatty phase, in particular consisting of fats that are liquid at 25 °C, such as vegetable oils, of mineral or synthetic origin, optionally volatile; fats that are solid at 25 °C such as vegetable waxes, of mineral or synthetic origin; pasty fats; gums; their mixtures.

[0263] Volatile oils are generally oils having, at 25 °C, a saturation vapor pressure of at least 0.5 millibar (or 50 Pa).

[0264] Among the constituents of the fatty phase, mention may be made of: • cyclic volatile silicones having from 3 to 8 silicon atoms, preferably from 4 to 6, • dimethylsiloxane / methylalkylsiloxane type cyclopolymers, • linear volatile silicones having from 2 to 9 silicon atoms, • volatile hydrocarbon oils, such as isoparaffins and in particular in particular, isododecane and fluorinated oils, • polyalkyl(Cl-C20) siloxanes and in particular those with trimethylsilyl end groups, including linear polydimethylsiloxanes and alkylmethylpolysiloxanes such as cetyldimethicone (CTFA name), • silicones modified by aliphatic and / or aromatic groups, optionally fluorinated, or by functional groups such as hydroxyl, thiol and / or amine groups, • phenylated silicone oils, • oils of vegetable or mineral origin and in particular, vegetable oils formed by fatty acid esters and polyols, in particular liquid triglycerides, for example sunflower, corn, soybean, pumpkin, grape seed, sesame, hazelnut, apricot, almond or avocado oils; fish oils, glycerol tricaprocaprylate or vegetable oils of formula Ri COOR2 in which RI represents the residue of a higher fatty acid including from 7 to 19 carbon atoms and R2 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms, for example, purcellin oil; paraffin oil, petroleum jelly, perhydrosqualene, wheat germ oil, calophyllum, sesame oil, macadamia oil, grape seed oil, rapeseed oil, coconut oil, peanut oil, palm oil, castor oil, jojoba oil, olive oil, argan oil or cereal germ oil; fatty acid esters; alcohols; acetylglycerides;octanoates, decanoates or ricinoleates of alcohol or polyalcohol; triglycerides of fatty acids; glycerides, ; • fluorinated and perfluorinated oils, • silicone gums, • vegetable, mineral or synthetic waxes such as microcrystalline waxes, paraffin, vaseline, petroleum jelly, ozokerite, montan wax; beeswax, lanolin and their derivatives; candelilla wax, ouricury wax, carnauba wax, Japan wax, cocoa butter, cork fiber wax or sugar cane waxes; hydrogenated oils solid at 25°C, ozokerites, fatty esters and glycerides solid at 25°C; polyethylene, polymethylene and waxes obtained by Fischer-Tropsch synthesis; hydrogenated oils solid at 25°C; lanolins; fatty acid esters solid at 25°C; silicone waxes; fluorinated waxes.

[0265] The composition according to the invention may also comprise adjuvants customary in the field in question, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents - in particular cosmetic or pharmaceutical -, active agents, preservatives, perfumes, fillers, thickening polymers, sequestering agents, pigments, pearlescent agents, UV filters, odor absorbers and colorants. These adjuvants, depending on their nature, can be introduced into the fatty phase, the aqueous phase and / or into lipid spherules.

[0266] The nature and quantity of these adjuvants can be chosen by a person skilled in the art, on the basis of his general knowledge, so as to obtain the desired form for the composition. In all cases, a person skilled in the art will take care to choose any additional compounds, and / or their quantity, so that the advantageous properties of the composition according to the invention are not, or not substantially, altered by the envisaged addition.

[0267] Preferably, the compositions according to the invention are presented in particular in the form of: • a product for the care, treatment, cleansing or protection of the skin of the face or body, such as a care composition (day, night, moisturizing) for the face or body; an anti-wrinkle or anti-aging composition for the face; a mattifying composition for the face; a composition for irritated skin; a makeup remover composition; a particularly moisturizing milk, optionally after-sun, for the body; • a sunscreen, an artificial tanning product (self-tanner) or an after-sun care product or • a makeup product for the skin of the face, body or lips, such as a foundation, tinted cream, blush or eye shadow, loose or compact powder, concealer stick, corrector stick, lipstick or lip care product.

[0268] The invention also relates to a non-therapeutic cosmetic care method for keratinous materials, in particular for the skin, comprising the application to the keratinous materials, in particular the skin, of a composition according to the invention.

[0269] The invention also relates to the cosmetic use of the composition of the invention for reducing the signs of skin aging. Preferably, the signs of skin aging are fine lines, wrinkles, thinning of the epidermis, strengthening of the skin barrier function and / or the appearance of flaccid and wrinkled skin.

[0270] Concrete, but non-limiting, examples illustrating the invention will be provided below.

[0271] In the examples, unless otherwise indicated, the temperature is room temperature (20°C) and expressed in degrees Celsius and the pressure is, unless otherwise indicated, atmospheric pressure.

[0272] In the examples, the quantities of the ingredients of the compositions are given in % by weight relative to the total weight of the composition (% by weight).

[0273] Example 1: Cosmetic composition according to the invention

[0274] The composition of the invention below is prepared according to the following protocol:

[0275] Heat phase A to 75°C. Prepare phase B in the appendix: mix and heat the components of phase B1 to 75°C then add B2. Introduce phase B onto phase A under shear at 75°C, then neutralize with phase C until the emulsion is homogeneous. Start cooling and add phase D under shear then disperse phase E below 50°C until a homogeneous emulsion is obtained.

[0276] [Tables 1] INCI Concentration (% by weight) Phase WATER Qsp 100 A GLYCOL 9.5 A NIACINAMIDE 3 A Preservatives Qs A STEARIC ACID 1.5 B1 GLYCERYL STEARATE (and) PEG-100 STEARATE 0.8 B1 OIL 7.5 B1 WAX 2.73 B1 ARACHIDYL ALCOHOL (and) BEHENYL ALCOHOL (and) ARACHIDYL GLUCOSIDE 2 B1 MYRISTYL MYRISTATE 1.23 B1 BIS-PEG / PPG-16 / 16 PEG / PPG-16 / 16 DL METHICONE (and) CAPRYLIC / CAPRIC TRIGLYCERIDE 0.9 B2 Base Qs C DIMETHICONE 2.5 D FATTY ALCOHOL 2 D Active agents and perfume 3.21 D XANTHAN GUM 0.25 D SODIUM POLYACRYLATE 0.8 D HYDROXYPROPYL TETRAHYDROPYRANTR1OE (Compound C-Glycoside) 14.3 (= 10% ma*) E D-PANTHENOL (75% of ma* in water) 1.34 (= 1% ma*) E

[0277] *ma = active ingredient

[0278] Example 2: In vitro evaluation of the complex of the invention

[0279] The complex of the invention was evaluated in vitro.

[0280] For this purpose, an aqueous solution comprising 10% by weight of active material of HYDROXYPROPYL TETRAHYDROPYRANTRIOL, 3% by weight of niacinamide and 1% by weight of active ingredient D-panthenol was used (complex of the invention).

[0281] An aqueous solution comprising 10% by weight of active material of HYDROXYPROPYL TETRAHYDROPYRANTRIOL only was also used as a reference (C-glycoside only).

[0282] Both solutions were tested on reconstructed skin (EpiKutis) and on an ex vivo model. Both mimic the effects of aging on the skin and validate the effectiveness of the test solutions. The protocols are as follows:

[0283] This test was divided into two parts: the first part was based on ex vivo skin tissues. The firming efficacy of the sample was evaluated by detecting changes in the contents of elastic fibers, elastin, chondroitin sulfate, and hyaluronic acid. The anti-wrinkle efficacy of the sample was evaluated by detecting changes in the contents of collagen fibers, Collagen III, and Collagen XVII. The second part was based on a 3D epidermal skin model (EpiKutis®). The soothing efficacy of the sample was evaluated by detecting changes in the contents of inflammatory cytokines (IL-1a, IL-8) and inflammatory mediators (PGE2). The restorative efficacy of the sample was evaluated by detecting changes in the content of Filaggrin (FLG). Test materials

[0284] Test system:

[0285] The model used in this trial was a reconstituted human epidermal skin model (EpiKutis®), the ex vivo skin tissue used in this trial was provided by Guangdong Biocell Biotechnology Co. Ltd.

[0286] Main reagents:

[0287] Ex vivo culture medium (Guangdong Biocell Biotechnology), PBS (Solarbio), Vitamin C (VC, Sigma), Vitamin E (VE, Sigma), Collagen III antibody (Abcam), Collagen XVII antibody (Abcam), Chondroitin sulfate antibody (Abcam), Paraformaldehyde (Biosharp), Masson kit (Shaanxi Yike Biotechnology), EpiGrowth culture medium (Guangdong Biocell Biotechnology), IL-1a ELISA kit (Abcam), IL-8 ELISA kit (Abcam), PGE2 ELISA kit (ENZO), FLG antibody (Abcam).

[0288] Main equipment:

[0289] CO2 incubator (Thermo, 1501), ultra-clean bench (Suzhou Antai, SW-CJ-1F), microplate reader (BioTek, Epoch), fluorescence microscope (Leica, DM2500), orthoscopic microscope (Olympus, BX53), UVA irradiation meter (Philips), UVB irradiation meter (Philips). Ex vivo skin tissue-based assays

[0290] Tissue treatment:

[0291] The freshly obtained skin tissue was immersed in 75% alcohol, washed for 30 s, and then cleaned three times with sterile PBS buffer; then, the skin tissue was cut into tissue blocks using a disposable sterile skin sampler, which had a fixed area size of 24 ± 2 mm. After treatment, the skin tissues were placed in the culture insert with the epidermis facing up and the dermis facing down. Then, the culture insert was transferred into a 6-well plate, and 3.7 mL of culture solution was added to each well for further culture at 37 °C with 5% CO2, the fresh culture solution was changed daily.

[0292] Administration:

[0293] After 2 days of skin tissue culture, UV irradiation and administration have were carried out according to the experimental groups and corresponding treatment conditions as follows: untreated skin, C-glycoside only, and the complex of the invention. Then, the skin tissues were exposed to UV irradiation (30J / cm2 UVA and 50mJ / cm2 UVB) for 4 consecutive days. After each irradiation, the fresh culture medium was replaced, and then the sample was applied to the skin surface. The positive control group (VC+VE) was administered under the liquid, and the sample group was administered on the surface. After 4 consecutive days of irradiation, the Ex vivo skin tissue was cultured for another 3 days during which no irradiation was performed and only sample administration was performed.

[0294] Detection of collagen fibers: Skin tissues were fixed with 4% paraformaldehyde, embedded, sectioned, and stained with Victoria blue and Masson's blue, respectively. The results were photographed and analyzed with Image-Pro® Plus software.

[0295] Immunofluorescence detection: The model rings were cut and fixed with 4% paraformaldehyde. After 24 hours of fixation, immunohistochemical detection was performed and images were taken under a microscope.

[0296] Calculation of the improvement rate:

[0297] Improvement rate (%) = (sample group - negative control group) / (negative control group) x 100%.

[0298] Statistical analysis of results: GraphPad Prism was used for plotting the curve and the result was expressed as Mean ± Standard Deviation. The t test was used for statistical analysis. The statistical analysis performed was two-tailed. P < 0.05 was considered as a significant difference, P < 0.01 is considered as having an extremely significant difference. EpiKutis® based trials

[0299] The working solution sample was prepared as follows: untreated skin, C-glycoside only and complex of the invention.

[0300] Administration and irradiation of the model:

[0301] 1) Model Administration: According to the test group as defined above, the The model was transferred to a 6-well plate and the model was randomly divided into blank control (BC), negative control (NC), positive control (PC; with 0.01 m / v dexamethasone) and control groups, with three replicates per group. 0.9 mL of model medium was added to each well of the BC and NC groups, and 0.9 mL of model medium containing dexamethasone was added to each well of the PC group. The administration was carried out on the surface of the sample group.

[0302] 2) UVB radiation: At the end of administration, except for the control group blank, the other groups were irradiated with UVB at a dose of 600 mJ / cm2.

[0303] 3) Incubation of the model: At the end of the irradiation, 6-well plates were incubated in a CO2 incubator (37°C, 5% CO2) for 24 h.

[0304] 4) Cleaning: At the end of the incubation, the residual test objects on the surface of the The model was cleaned with sterile PBS and the residual liquid inside and outside the model was wiped off with sterile cotton swabs.

[0305] ELISA detection:

[0306] After incubation for 24 h, the culture medium of the 3D epidermal skin model was collected in a centrifuge tube. After collection, the samples for ELISA detection were stored in a refrigerator at -80 °C and the detection and analysis were carried out according to the procedure of the ELISA kit.

[0307] Detection by immunofluorescence:

[0308] The models used for detection were fixed with 4% paraformaldehyde. After 24 hours of fixation, immunofluorescence detection was performed and photographs were taken under a microscope.

[0309] Calculation of inhibition rate and improvement rate

[0310] Inhibition rate (%) = (negative control group - sample group) / (negative control group) x 100%.

[0311] Improvement rate (%) = (sample group - negative control group) / (negative control group) x 100%.

[0312] Statistical analysis of the results:

[0313] GraphPad Prism software was used to analyze the data, the result was expressed as Mean ± Standard Deviation. Comparisons between groups were performed using t-test statistical analysis. The statistical analysis performed was two-tailed. P < 0.05 was considered a significant difference, P < 0.01 was considered an extremely significant difference. Test results

[0314] The results are summarized in the table below.

[0315] [Table 2]

[0316] Increase or decrease in expression (%) of the following markers after UVB irradiation Marker Filagg rine (EpiK utis) IL-1a (EpiK utis) IL-8 (EpiK utis) PGE2 (EpiK utis) Coll XVII (ex vivo) Collagen fibers (ex vivo) Coll III (ex vivo) Sulfated GAGs (ex vivo) C-glycoside only1 +35.71 -25.52 -46.98 -20.91 +79.17 +200 +146.88 +46.15 Complex of the invention2 +178.57 -74.95 -76.94 -68.43 +212.5 +312.5 +303.13 +105.13 Efficacy of the complex of the invention compared to C-glycoside alone 5 times more effective 2.9 times more effective 1.6 times more effective effective 3.2 times more effective 2.6 times more effective 1.5 times more effective 2 times more effective 2.2 times more effective Significance of C-glycoside alone compared to the complex of the invention P = 0.0 01** P = 0.0 00** P = 0.0 00** P = 0.0 00** P = 0.0 05** P = 0.0 08** P = 0.0 02** P = 0.0 45*

[0317] 1 Increase or decrease in expression (%) with HYDROXYPROPYL TETRA- HYDROPYRANTRIOL compared to untreated skin

[0318] 2 Increase or decrease in expression (%) with the complex of the invention (HYDROXYPROPYL TETRAHYDROPYRANTRIOL, niacinamide and D-panthenol) compared to untreated skin

[0319] Filaggrin is a marker of keratinocyte differentiation and good barrier function. When skin aging is induced in the model, filaggrin expression decreases. With C-glycoside, filaggrin increases and, with the complex of the invention, it is significantly better even compared to C-glycoside alone.

[0320] IL-1a, IL-8 and PGE2 are inflammatory markers. When skin aging is induced on the model, these inflammatory markers increase in the epidermis. Thanks to C-glycoside, the inflammatory markers are inhibited and, with the complex of the invention, this is significantly better even than with C-glycoside alone.

[0321] Collagen XVII is a marker of keratinocyte renewal and skin regeneration. When skin aging is induced in the model, the expression of collagen XVII decreases. Thanks to C-glycoside, collagen XVII increases and, with the complex of the invention, it is even significantly better than with C-glycoside alone.

[0322] Collagen fibers are important for the structure of the dermis. When skin aging is induced on the model, the expression of collagen fibers decreases. Thanks to C-glycoside, the expression of collagen fibers increases and, with the complex of the invention, it is even significantly better than with C-glycoside alone.

[0323] Collagen III is important for the structure of the dermis. When skin aging is induced on the model, the expression of collagen III decreases. Thanks to C-glycoside, collagen III increases and, with the complex of the invention, it is even significantly better than with C-glycoside alone.

[0324] Chondroitin sulfate, a type of GAG, is an important component of the extracellular matrix of the dermis. When skin aging is induced in the model, the expression of sulfated GAG decreases. Thanks to C-glycoside, sulfated GAG increases and, with the complex of the invention, it is even significantly better than with C-glycoside alone.

[0325] Thus, among these 8 epidermal and dermal markers, the complex of the invention shows an in vitro efficacy significantly better than that of C-glycoside (HYDROXYPROPYL TETRAHYDROPYRANTRIOL) alone.

Claims

Claims

1. Cosmetic composition comprising, in a physiologically acceptable medium, by weight relative to the total weight of the composition: from 1% to 25% by weight of active substance of at least one C-glycoside of formula (I), from 1% to 10% by weight of active substance of a compound chosen from niacinamide and its derivatives and from 0.5% to 10% by weight of active ingredient panthenol, wherein formula (I) is: [Chem.l] ,X - R (I) in which: - R represents: O a linear saturated alkyl radical in C1 to C20, in particular in C1 to C10, or unsaturated in C2 to C20, in particular in C3 to C10, or a branched or cyclic saturated or unsaturated alkyl radical in C3 to C20, in particular in C4 to C10; O a linear hydrofluoro- or perfluoro-alkyl radical saturated in C1 to C20, in particular in C2 to C10, or unsaturated in C2 to C20, in particular in C2 to C10, or branched or cyclic, saturated or unsaturated, in C3 to C20, in particular in C4 to C10; O a phenyl or benzyl radical, the hydrocarbon chain forming said radicals being optionally interrupted, where appropriate, by 1, 2, 3 or more heteroatoms chosen from: O an oxygen, O a sulfur, O a nitrogen and O a silicone, and being optionally substituted by at least one radical chosen from: O -OR4, O -SR4, O -NR4R5, O -COOR4, O -CONHR4,

2. O-CN, O a halogen atony, O a hydrofluoro- or perfluoro-alkyl radical in C1 to C6 and / or O a C3 to C8 cycloalkyl radical and / or O at least one optionally substituted C5 to C18 cycloalkyl, aryl, heterocyclic radical, - where R4 and R5 may represent, independently of one another, a hydrogen atom, or a saturated C1 to C30, in particular C3 to C12, or unsaturated C2 to C30, in particular C3 to C12, linear, or saturated or unsaturated C3 to C30, in particular C4 to C12, branched or cyclic alkyl, perfluoroalkyl or hydrofluoroalkyl radical; or a C6 to C10 aryl radical, - X represents a radical chosen from -CO-, -CH(OH)- or -CH(NH2)- and, preferably, a -CH(OH)- group; - S represents a monosaccharide or a polysaccharide including up to 20 sugar units, in particular up to 6 sugar units, in the form of pyranose and / or furanose and of the L and / or D series, said mono- or polysaccharide being optionally substituted by a necessarily free hydroxyl group and optionally one or more optionally protected amine functions, and - the S-CH2-X bond represents a C-anomeric bond, which can be a or [3 or one of its physiologically acceptable salts, its solvates such as its hydrates or its isomers. Composition according to claim 1, in which the C-glycoside of formula (I) is chosen from:

1. C-[3-D-xylopyranoside-n-propane-2-one; 2. CaD-xylopyranoside-n-propane-2-one; 3. l-[2-(3-hydroxy-propylamino)-propyl]- C-[3-D-xylopyranose; 4. 1-[2-(3-hydroxy-propylamino)-propyl]-CaD-xylopyranose; 5. C-[3-D-xylopyranoside-2-hydroxy-propane; 6. CaD-xylopyranoside-2-hydroxy-propane; 7. C-[3-D-xylopyranoside-2-amino-propane; 8. CaD-xylopyranoside-2-amino-propane; 9. C-[3-D-xylopyranoside-2-phenylamino-propane; 10. CaD-xylopyranoside-2-phenylamino-propane; 11. Ethyl ester of acid 3-methyl-4-(C-[3-D-xylopyranoside)-butyric acid; 12. Ethyl ester of acid 3-methyl-4-(CaD-xylopyranoside)-butyric acid; 13. 6-(C-[3-D-xylopyranoside)-5-keto-hexanoic acid; 14. 6-(CaD-xylopyranoside)-5-keto-hexanoic acid; 15. 6-(C-[3-D-xylopyranoside)-5-hydroxy-hexanoic acid; 16. 6-(CaD-xylopyranoside)-5-hydroxy-hexanoic acid; 17. 6-(C-[3-D-xylopyranoside)-5-amino-hexanoic acid; 18. 6-(CaD-xylopyranoside)-5-amino-hexanoic acid; 19. 6-(C-[3-D-xylopyranoside)-5-phenylaminohexanoic acid; 20. 6-(CaD-xylopyranoside)-5-phenylamino-hexanoic acid; 21. l-(C-[3-D-xylopyranoside)-hexane-2,6-diol; 22. l-(CaD-xylopyranoside)-hexane-2,6-diol; 23. 5-(C-[3-D-xylopyranoside)-4-keto-pentanoic acid; 24. 5-(CaD-xylopyranoside)-4-keto-pentanoic acid; 25. 5-(C-[3-D-xylopyranoside)-4-hydroxy-pentanoic acid; 26. 5-(CaD-xylopyranoside)-4-hydroxy-pentanoic acid; 27. 5-(C-[3-D-xylopyranoside)-4-amino-pentanoic acid; 28. 5-(CaD-xylopyranoside)-4-amino-pentanoic acid; 29. 5-(C-[3-D-xylopyranoside)-4-phenylamino-pentanoic acid; 30. 5-(CaD-xylopyranoside)-4-phenylamino-pentanoic acid; 31. l-(C-[3-D-xylopyranoside)-pentan-2,5-diol; 32. l-(CaD-xylopyranoside)-pentan-2,5-diol; 33. l-(C-[3-D-fucopyranoside)-propane-2-one; 34. l-(CaD-fucopyranoside)-propane-2-one; 35. l-(C-[3-L-fucopyranoside)-propane-2-one; 36. l-(CaL-fucopyranoside)-propane-2-one; 37. l-(C-[3-D-fucopyranoside)-2-hydroxy-propane; 38. l-(CaD-fucopyranoside)-2-hydroxy-propane; 39. l-(C-[3-L-fucopyranoside)-2-hydroxy-propane; 40. l-(CaL-fucopyranoside)-2-hydroxy-propane; 41. l-(C-[3-D-fucopyranoside)-2-amino-propane; 42. l-(CaD-fucopyranoside)-2-amino-propane; 43. l-(C-[3-L-fucopyranoside)-2-amino-propane; 44. l-(CaL-fucopyranoside)-2-amino-propane; 45. l-(C-[3-D-fucopyranoside)-2-phenylamino-propane; 46. ​​l-(CaD-fucopyranoside)-2-phenylamino-propane; 47. l-(C-[3-L-fucopyranoside)-2-phenylamino-propane; 48. l-(CaL-fucopyranoside)-2-phenylamino-propane; 49. Ethyl ester of acid 3-methyl-4-(C-(3-D-fucopyranoside)-butyric acid; 50. Ethyl ester of acid 3-methyl-4-(CaD-fucopyranoside)-butyric acid; 51. Ethyl ester of acid 3-methyl-4-(C-[3-L-fucopyranoside)-butyric acid; 52. Ethyl ester of acid 3-methyl-4-(CaL-fucopyranoside)-butyric acid; 53. 6-(C-[3-D-fucopyranoside)-5-keto-hexanoic acid; 54. 6-(CaD-fucopyranoside)-5-keto-hexanoic acid; 55. 6-(C-[3-L-fucopyranoside)-5-keto-hexanoic acid; 56. 6-(CaL-fucopyranoside)-5-keto-hexanoic acid; 57. 6-(C-[3-D-fucopyranoside)-5-hydroxy-hexanoic acid; 58. 6-(CaD-fucopyranoside)-5-hydroxy-hexanoic acid; 59. 6-(C-[3-L-fucopyranoside)-5-hydroxy-hexanoic acid; 60. 6-(CaL-fucopyranoside)-5-hydroxy-hexanoic acid; 61. 6-(C-(3-D-fucopyranoside)-5-amino-hexanoic acid; 62. 6-(CaD-fucopyranoside)-5-amino-hexanoic acid; 63. 6-(C-[3-L-fucopyranoside)-5-amino-hexanoic acid; 64. 6-(CaL-fucopyranoside)-5-amino-hexanoic acid; 65. l-(C-|3-D-fucopyranoside)-hexane-2,6-diol; 66. l-(CaD-fucopyranoside)-hexane-2,6-diol; 67. l-(C-|3-L-fucopyranoside)-hexane-2,6-diol; 68. l-(CaL-fucopyranoside)-hexane-2,6-diol; 69. 5-(C-[3-D-fucopyranoside)-4-keto-pentanoic acid; 70. 5-(CaD-fucopyranoside)-4-keto-pentanoic acid; 71. Acid 5-(C-[3-L-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid; 72. Acid 5-(CaL-fucopyranoside)-hexane-2,6-diol)-4-ketopentanoic acid; 73. 5-(C-[3-D-fucopyranoside)-4-hydroxy-pentanoic acid; 74. 5-(CaD-fucopyranoside)-4-hydroxy-pentanoic acid; 75. 5-(C-[3-L-fucopyranoside)-4-hydroxy-pentanoic acid; 76. 5-(CaL-fucopyranoside)-4-hydroxy-pentanoic acid; 77. 5-(C-[3-D-fucopyranoside)-4-amino-pentanoic acid; 78. 5-(CaD-fucopyranoside)-4-amino-pentanoic acid; 79. 5-(C-[3-L-fucopyranoside)-4-amino-pentanoic acid; 80. 5-(CaL-fucopyranoside)-4-amino-pentanoic acid; 81. l-(C-|3-D-fucopyranoside)-pentane-2,5-diol; 82. l-(CaD-fucopyranoside)-pentane-2,5-diol; 83. l-(C-[3-L-fucopyranoside)-pentane-2,5-diol; 84. l-(CaL-fucopyranoside)-pentane-2,5-diol; 85. l-(C-[3-D-glucopyranosyl)-2-hydroxy-propane; 86. l-(CaD-glucopyranosyl)-2-hydroxy-propane; 87. l-(CPD-glucopyranosyl)-2-amino-propane; 88. l-(CaD-glucopyranosyl)-2-amino-propane; 89. l-(CPD-glucopyranosyl)-2-phenylamino-propane; 90. l-(CaD-glucopyranosyl)-2-phenylamino-propane; 91. Ethyl ester of acid 3-methyl-4-(C-[3-D-glucopyranosyl)-butyric acid; 92. Ethyl ester of acid 3-methyl-4-(CaD-glucopyranosyl)-butyric acid; 93. 6-(C-[3-D-glucopyranosyl)-5-keto-hexanoic acid; 94. 6-(CaD-glucopyranosyl)-5-keto-hexanoic acid; 95. Acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-hexanoïque ; 96. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-hexanoïque ; 97. Acide 6-(C-[3-D-glucopyranosyl)-5-amino-hexanoïque ; 98. Acide 6-(C-a-D-glucopyranosyl)-5-amino-hexanoïque ; 99. Acide 6-(C-[3-D-glucopyranosyl)-5-phénylamino-hexanoïque ; 100. Acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-hexanoïque ; 101. l-(C-[3-D-glucopyranosyl)-hexane-2,6-diol ; 102. l-(C-a-D-glucopyranosyl)-hexane-2,6-diol ; 103. Acide 6-(C-[3-D-glucopyranosyl)-5-céto-pentanoïque ; 104. Acide 6-(C-a-D-glucopyranosyl)-5-céto-pentanoïque ; 105. Acide 6-(C-[3-D-glucopyranosyl)-5-hydroxy-pentanoïque ; 106. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoïque ; 107. Acide 6-(C-[3-D-glucopyranosyl)-5-amino-pentanoïque ; 108. Acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoïque ; 109. 6-(C-[3-D-glucopyranosyl)-5-phenylamino-pentanoic acid; 110. 6-(CaD-glucopyranosyl)-5-phenylamino-pentanoic acid; 111. l-(C-[3-D-glucopyranosyl)-pentane-2,5-diol; 112. l-(CaD-glucopyranosyl)-pentane-2,5-diol; 113. l-(C-[3-D-galactopyranosyl)-2-hydroxy-propane; 114. l-(CaD-galactopyranosyl)-2-hydroxy-propane; 115. l-(C-[3-D-galactopyranosyl)-2-amino-propane; 116. l-(CaD-galactopyranosyl)-2-amino-propane; 117. l-(C-[3-D-galactopyranosyl)-2-phenylamino-propane; 118. l-(CaD-galactopyranosyl)-2-phenylamino-propane; 119. Ethyl ester of acid 3-methyl-4-([3-D-galactopyranosyl)-butyric acid; 120. Ethyl ester of acid 3-methyl-4-(aD-galactopyranosyl)-butyric acid; 121. 6-(C-[3-D-galactopyranosyl)-5-keto-hexanoic acid; 122. 6-(CaD-galactopyranosyl)-5-keto-hexanoic acid; 123. 6-(C-β-D-galactopyranosyl)-5-hydroxy-hexanoic acid; 124. 6-(C-α-D-galactopyranosyl)-5-hydroxy-hexanoic acid; 125. 6-(C-β-D-galactopyranosyl)-5-amino-hexanoic acid; 126. 6-(C-α-D-galactopyranosyl)-5-amino-hexanoic acid; 127. 6-(C-β-D-galactopyranosyl)5-phenylamino-hexanoic acid; 128. 6-(C-α-D-galactopyranosyl)5-phenylamino-hexanoic acid; 129. 1-(C-β-D-galactopyranosyl)-hexane-2,6-diol; 130. 1-(C-α-D-galactopyranosyl)-hexane-2,6-diol; 131. 6-(C-β-D-galactopyranosyl)-5-oxo-pentanoic acid; 132. 6-(C-α-D-galactopyranosyl)-5-oxo-pentanoic acid; 133. 6-(C-β-D-galactopyranosyl)-5-hydroxy-pentanoic acid; 134. 6-(C-α-D-galactopyranosyl)-5-hydroxy-pentanoic acid; 135. 6-(C-β-D-galactopyranosyl)-5-amino-pentanoic acid; 136. 6-(CaD-galactopyranosyl)-5-amino-pentanoic acid; 137. 6-(C-[3-D-galactopyranosyl)-5-phenylamino-pentanoic acid; 138. 6-(CaD-galactopyranosyl)-5-phenylamino-pentanoic acid; 139. l-(C-[3-D-galactopyranosyl)-pentan-2,6-diol; 140. l-(CaD-galactopyranosyl)-pentan-2,6-diol; 141. l-(C-[3-D-fucofuranosyl)-propane-2-one; 142. l-(CaD-fucofuranosyl)-propane-2-one; 143. l-(C-[3-L-fucofuranosyl)-propane-2-one; 144. l-(CaL-fucofuranosyl)-propane-2-one; 145. 3'-(acetamido-C-[3-D-glucopyranosyl)-propane-2'-on; 146. 3'-(acetamido-CaD-glucopyranosyl)-propan-2'-one; 147. l-(acetamido-C-[3-D-glucopyranosyl)-2-hydroxyl-propane; 148. l-(acetamido-C-[3-D-glucopyranosyl)-2-amino-propane; 149. l-(acetamido-C-[3-D-glucopyranosyl)-2-phenylamino-propane; 150. l-(acetamido-CaD-glucopyranosyl)-2-phenylamino-propane; 151. 3-Methyl-4-(acetamido-C-[3-D-glucopyranosyl]-butyric acid ethyl ester 152. 3-Methyl-4-(acetamido-CaD-)-ethyl ester glucopyranosyl)-butyric acid 153. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-keto-hexanoic acid; 154. 6-(Acetamido-CaD-glucopyranosyl)-5-keto-hexanoic acid; 155. Acid 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-hexanoic acid; 156. Acid 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-hexanoic acid; 157. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-amino-hexanoic acid; 158. 6-(Acetamido-CaD-glucopyranosyl)-5-amino-hexanoic acid; 159. Acid 6-(acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-hexanoic acid; 160. Acid 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-hexanoic acid; 161. l-(acetamido-C-[3-D-glucopyranosyl)-hexane-2,6-diol; 162. l-(acetamido-CaD-glucopyranosyl)-hexane-2,6-diol; 163. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-keto-pentanoic acid; 164. 6-(Acetamido-CaD-glucopyranosyl)-5-keto-pentanoic acid; 165. Acid 6-(acetamido-C-[3-D-glucopyranosyl)-5-hydroxy-pentanoic acid; 166. Acid 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-pentanoic acid; 167. 6-(Acetamido-C-[3-D-glucopyranosyl)-5-amino-pentanoic acid; 168. Acid 6-(acetamido-CaD-glucopyranosyl)-5-amino-pentanoic acid; 169. Acid 6-(acetamido-C-[3-D-glucopyranosyl)-5-phenylamino-pentanoic acid; 170. Acid 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-pentanoic acid; 171. l-(acetamido-C-[3-D-glucopyranosyl)-pentane-2,5-diol; and 172. l-(acetamido-CaD-glucopyranosyl)-pentane-2,5-diol, preferably, the C-glycoside of formula (I) is chosen from: - C-[3-D-xylopyranoside-n-propane-2-one, - Ca-D-xylopyranoside-n-propane-2-one, - C-[3-D-xylopyranoside-2-hydroxy-propane, - Ca-D-xylopyranoside-2-hydroxy-propane, - l-(C-[3-D-fucopyranoside)-propane-2-one, - l-(CaD-fucopyranoside)-propane-2-one, - l-(C-[3-L-fucopyranoside)-propane-2-one, - l-(C-a-L-fucopyranoside)-propane-2-one, - l-(C-[3-D-fucopyranoside)-2-hydroxy-propane, - l-(C-a-D-fucopyranoside)-2-hydroxy-propane, - l-(C-[3-L-fucopyranoside)-2-hydroxy-propane, - l-(C-a-L-fucopyranoside)-2-hydroxy-propane, - l-(C-[3-D-Glucopyranosyl)-2-hydroxyl-propane, - l-(C-a-D-Glucopyranosyl)-2-hydroxyl-propane, - l-(C-[3-D-galactopyranosyl)-2-hydroxyl-propane, - l-(C-a-D-galactopyranosyl)-2-hydroxyl-propane - l-(C-[3-D-fucofuranosyl)-propane-2-one, - l-(C-a-D-fucofuranosyl)-propane-2-one - l-(C-[3-L-fucofuranosyl)-propane-2-one, - l-(C-a-L-fucofuranosyl)-propane-2-one, - C-[3-D-maltopyranoside-n-propane-2-one, - C-a-D-maltopyranoside-n-propane-2-one - C-[3-D-maltopyranoside-2-hydroxy-propane, et - C-a-D-maltopyranoside-2-hydroxy-propane.

3. Composition according to any one of the preceding claims, wherein the C-glycoside of formula (I) is chosen from C-beta-D-xylopyranoside-2-hydroxy-propane and C-alpha-D-xylopyranoside-2-hydroxy-propane, preferably C-beta-D-xylopyranoside-2-hydroxy-propane.

4. Composition according to any one of the preceding claims, which comprises at least one C-glycoside of formula (I) at a content of 5% to 18% by weight of active substance relative to the total weight of the composition, and preferably of 7% to 15% by weight of active substance.

5. A composition according to any preceding claim, which comprises from 1% to 8% by weight of the compound selected from niacinamide and its derivatives relative to the total weight of the composition, preferably from 1% to 5% by weight, preferably from 2% to 4% by weight.

6. A composition according to any preceding claim, which comprises from 0.7% to 8% by weight of active substance relative to the total weight of the panthenol composition, preferably from 0.8% to 5% by weight, preferably from 0.8% to 1.5% by weight.

7. Composition according to any one of the preceding claims, which comprises an aqueous phase and / or a fatty phase; preferably the aqueous phase comprises water, floral water and / or mineral water; and optionally one or more organic solvents such as than a C1-C8 alcohol, in particular ethanol, isopropanol, tert-butanol, n-butanol, pentanol, hexanol, polyols such as glycerin, propylene glycol, butylene glycol, capryl / caprylic glycol, isoprene glycol, polyethylene glycol and polyol ethers; preferably the fatty phase comprises fats which are liquid at 25°C, such as vegetable oils, of mineral or synthetic origin, optionally volatile; fats which are solid at 25°C such as vegetable waxes, of mineral or synthetic origin; pasty fats; gums; and / or mixtures thereof.

8. Composition according to any one of the preceding claims, which is in the form of an aqueous or oily solution; a dispersion of the lotion or serum type; an emulsion of liquid or semi-liquid consistency of the milk type obtained by dispersing a fatty phase in aqueous phase (O / W), inversely (W / O), or triple O / W / O or W / O / W; a suspension or emulsion of soft consistency of the aqueous or anhydrous cream or gel type; microcapsules or microparticles; vesicular dispersions of ionic and / or non-ionic type.

9. Non-therapeutic cosmetic care process for keratinous materials, in particular the skin, comprising the application to the keratinous materials, in particular the skin, of a composition according to any one of claims 1 to 8.

10. Cosmetic use of the composition according to any one of claims 1 to 8 for reducing the signs of skin aging, preferably the signs of skin aging are fine lines, wrinkles, thinning of the epidermis, strengthening of the skin barrier function and / or the appearance of flaccid and wrinkled skin.